Alcohol use disorder (AUD) is a chronic, relapsing brain condition defined by impaired control over drinking despite mounting harm to health, work, and relationships. About 29.5 million Americans aged 12 and older met DSM-5-TR criteria for AUD in 2022 (SAMHSA NSDUH), and globally alcohol contributes to roughly 2.6 million deaths per year.

Alcohol use disorder (ICD-10: F10.10-F10.99) is the DSM-5-TR diagnosis that replaced the older categorical split of alcohol abuse and alcohol dependence in 2013. It is defined by a pattern of alcohol use leading to clinically significant impairment, with at least 2 of 11 criteria within a 12-month period: drinking more or longer than intended, persistent desire or unsuccessful efforts to cut down, large time spent obtaining or recovering from drinking, craving, role failure, interpersonal problems, giving up activities, hazardous use, continued use despite harm, tolerance, and withdrawal. Severity is graded as mild (2-3 criteria), moderate (4-5), or severe (≥6). AUD is a brain disorder involving reward-system dysregulation (mesolimbic dopamine), stress-system upregulation (extended amygdala corticotropin-releasing factor), and prefrontal executive impairment, all of which persist long after acute intoxication or withdrawal resolves.
The key symptoms of Alcohol Use Disorder are: Drinking more alcohol or for longer periods than originally intended on most occasions over the past year., Repeated unsuccessful attempts to cut down or stop drinking, including failed promises to oneself or others., Significant time spent obtaining alcohol, drinking, or recovering from drinking — sometimes hours each day., Strong cravings or urges to drink, often triggered by specific places, people, emotions, or times of day., Continued drinking despite recurring problems at work, school, or home such as absenteeism, missed responsibilities, or poor performance., Continued drinking despite ongoing interpersonal problems caused or worsened by alcohol use., Giving up or reducing important social, occupational, or recreational activities because of drinking..
Diagnosis is clinical, made by interview using the DSM-5-TR criteria — a person who meets 2 or more of 11 criteria within a 12-month period has AUD, with severity graded by criterion count. Screening should be universal in primary care; the AUDIT (Alcohol Use Disorders Identification Test) is the WHO-validated 10-item instrument with sensitivity over 90% at a cutoff of 8. The 3-item AUDIT-C is the most common short version used in busy practice; a score of 4+ in men or 3+ in women triggers further assessment. The single-question screen — 'How many times in the past year have you had X or more drinks in a day?' (5 for men, 4 for women) — is over 80% sensitive. After a positive screen, a structured DSM-5-TR criterion review establishes the diagnosis and severity. Biomarkers play a secondary role: gamma-glutamyl transferase, mean corpuscular volume, carbohydrate-deficient transferrin, and phosphatidylethanol (PEth) can support the diagnosis or monitor abstinence, but none are sensitive or specific enough to replace clinical interview. Always assess comorbid conditions: depression and anxiety screening, suicide risk, hepatic function (ALT, AST, GGT, INR, platelets, albumin), nutritional status, and withdrawal risk using the CIWA-Ar scale if recent heavy use. Distinguish AUD from primary mood and anxiety disorders by attending to which preceded the other and how symptoms behave during periods of sobriety lasting at least 4 weeks.
AUD is a chronic relapsing condition with outcomes comparable to type 2 diabetes or hypertension in adherence-corrected analyses. Roughly one-third of people achieve sustained remission (no recurrence at 1 year) after a single course of evidence-based treatment, another third achieve substantial reduction in drinking and harm without full abstinence, and the remaining third return to problematic use within 12 months. Relapse rates fall over time: at 5 years of continuous abstinence, the annual relapse rate drops to under 10%. Medications combined with behavioral therapy roughly double abstinence rates compared with no treatment. Long-term mortality from AUD is significantly elevated — 26-fold higher than population baseline in severe AUD, driven by liver disease, cardiovascular events, accidents, and suicide. Untreated, life expectancy is reduced by an average of 24-28 years compared to people without AUD (Westman 2015 Scandinavian cohort). Treated patients reach population-typical life expectancy when sustained abstinence is achieved before significant organ damage.
A psychiatrist or addiction medicine specialist should be involved for moderate-to-severe AUD, for patients with co-occurring psychiatric disorders, after failed initial treatment, for medically complex withdrawal, or where extended-release injectable medications and structured intensive outpatient programs are needed. Primary care can effectively manage mild AUD with brief intervention plus oral naltrexone or acamprosate, and screening should always begin in primary care.
Find specialists →Acute withdrawal resolves over 3-7 days with appropriate management. Post-acute withdrawal — sleep disturbance, mood instability, craving — lasts 2-12 weeks. Cognitive recovery from chronic alcohol exposure continues over 6-24 months. Liver enzymes normalize within 6-8 weeks of abstinence in the absence of cirrhosis. Most patients describe meaningful quality-of-life improvement within 3 months. Long-term remission rates rise progressively with each year of continuous abstinence, with the steepest reduction in relapse risk during years 1-5.
Regular aerobic exercise (30 minutes most days) reduces craving, improves mood, and supports sleep — all major drivers of relapse. Strength training twice weekly counters sarcopenia from chronic alcohol use. Avoid high-intensity exercise during the first 5-7 days of withdrawal due to autonomic instability. Group exercise classes can substitute for the social rituals previously built around drinking.
Look for board certification in addiction psychiatry or addiction medicine, comfort prescribing all three FDA-approved AUD medications, willingness to incorporate harm-reduction goals where appropriate, and availability of structured behavioral therapy on-site or by warm referral. Continuity matters — AUD recovery is a multi-year process and a long-term clinical relationship outperforms episodic referrals. Ask whether the practice integrates mental-health treatment for common comorbidities (depression, anxiety, PTSD).
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in Argentina.
Apply as specialist →Specialists who treat Alcohol Use Disorder. Get expert guidance and personalized care.